AI Article Synopsis
- - Previous studies showed that certain treatments improved behavior in Ts65Dn mice (a model of Down syndrome), but translating these findings into successful human trials has been challenging due to factors like timing, model selection, and unclear endpoints.
- - Failures in human trials can be attributed to selecting inappropriate animal models and a lack of direct relevance to human conditions.
- - The focus is now shifting to using human cell models to better understand the molecular causes of Down syndrome, which could help in identifying and testing new therapies before moving to human trials.
Article Abstract
While preclinical studies have reported improvement of behavioral deficits in the Ts65Dn mouse model of Down syndrome (DS), translation to human clinical trials to improve cognition in individuals with DS has had a poor success record. Timing of the intervention, choice of animal models, strategy for drug selection, and lack of translational endpoints between animals and humans contributed to prior failures of human clinical trials. Here, we focus on in vitro cell models from humans with DS to identify the molecular mechanisms underlying the brain phenotype associated with DS. We emphasize the importance of using these cell models to screen for therapeutic molecules, followed by validating them in the most suitable animal models prior to initiating human clinical trials.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997046 | PMC |
| http://dx.doi.org/10.1016/j.molmed.2019.10.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!